Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05004350
Other study ID # W00090GE202
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 14, 2021
Est. completion date January 11, 2025

Study information

Verified date June 2024
Source Pierre Fabre Medicament
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 103
Est. completion date January 11, 2025
Est. primary completion date December 19, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for Molecular Prescreening: The following inclusion criteria must be met for a participant to be eligible to undergo molecular tumor prescreening: - Chinese male or female participant with age =18 years at the time of informed consent. - Histologically- or cytologically-confirmed colorectal cancer (CRC) that is metastatic. - Eligible to receive cetuximab per Chinese approved label with regard to tumor Rat Sarcoma Viral Oncogene Homologue (RAS) mutation status (i.e. approved for Rat Sarcoma Viral Oncogene Homologue Wild Type(RAS wt) status). - Able to provide a sufficient amount of representative tumor specimen for central prospective laboratory testing of B-RAF Proto-oncogene, Serine/threonine Kinase (BRAF) mutation status and also retrospective RAS wt status and Microsatellite Instability (MSI) testing. Inclusion Criteria for Treatment Period: The following inclusion criteria must be met for a participant to be eligible for this study: - Chinese male or female participant with age =18 years at time of informed consent. - Histologically or cytologically confirmed CRC that is metastatic and unresectable at time of study entry (i.e. not suitable for complete surgical resection at screening). - Presence of a BRAF V600E mutation in tumor tissue previously determined by a local assay at any time before screening or by the central laboratory. NOTE: Other protocol defined Inclusion criteria may apply Exclusion Criteria for Molecular Prescreening: Participants meeting any of the following criteria are not eligible to undergo molecular tumor prescreening: - Prior anti-Epidermal Growth Factor Receptor (anti-EGFR) treatment - More than two prior regimens in the metastatic setting. - Known contraindication to receive cetuximab or irinotecan at the planned dose according to the most recent cetuximab and irinotecan local label. - Known history of Gilbert's syndrome or is known to have any of the following genotypes: uridine 5'-diphospho-glucuronosyltransferase (UGT)1A1*6/*6, UGT1A1*28/*28 or UGT1A1*6/*28. - Leptomeningeal disease. Exclusion Criteria for Treatment Period: - Prior treatment with any Proto oncogene Serine/threonine-Protein Kinase (RAF) inhibitor, cetuximab, panitumumab or other EGFR inhibitors. - Symptomatic brain metastasis. - Leptomeningeal disease. - Use of any herbal medications/supplements or any medications or foods that are moderate or strong inhibitors or inducers of cytochrome P450 (CYP)3A4/5 =1 week before the start of study intervention. - Known history of acute or chronic pancreatitis within 6 months before the start of study intervention. NOTE: Other protocol defined Exclusion criteria may apply

Study Design


Intervention

Drug:
Encorafenib
oral hard capsule
Cetuximab
intravenous infusion
FOLFIRI
Combination of: irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion

Locations

Country Name City State
China The Affiliated Hospital of Hebei University Baoding Hebei
China Beijing Cancer Hospital Beijing Beijing
China Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing Beijing
China The First Hospital of Jilin University Changchun Jilin
China Xiangya Hospital Central South University Changsha Hunan
China The First People's Hospital of Changzhou Changzhou Jiangsu
China The First People's Hospital of Foshan Foshan Guangdong
China Fujian Medical University - Fujian Provincial Cancer Hospital Fuzhou Fujian
China First Affiliated Hospital of Gannan Medical University Ganzhou Jiangxi
China Cancer Center of Guangzhou Medical University Guangzhou Guangdong
China The Sixth Affiliated Hospital Sun Yat-Sen University Guangzhou Guangdong
China Sir Run Run Shaw Hospital - Zhejiang University School of Medicine Hangzhou Zhejiang
China The First Affiliated Hospital - Zhejiang University School of Medicine Hangzhou Zhejiang
China Harbin Medical University Cancer Hospital Harbin Heilongjiang
China The First Affiliated Hospital of Jinzhou Medical University Jinzhou Liaoning
China The First Affiliated Hospital of Nanchang University Nanchang Jiangxi
China The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi
China The Second People's Hospital of Neijiang Neijiang Sichuan
China Huashan Hospital Fudan University Shanghai Shanghai
China Shanghai East Hospital, Tongji University Shanghai Shanghai
China Xinhua Hospital Affilliated to Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China Zhongshan Hospital Fudan University Shanghai Shanghai
China Cancer Hospital Affiliated to Shantou University Medical College Shantou Guangdong
China Liaoning Cancer Hospital & Institute Shenyang Liaoning
China The First Hospital of China Medical University Shenyang Liaoning
China Peking University Shenzhen Hospital Shenzhen Guangdong
China Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin
China Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei
China Union Hospital Tongji medical college Huazhong University of Science and Technology Wuhan Hubei
China Zhongnan Hospital of Wuhan University Wuhan Hubei
China Shaanxi Provincial People's Hospital Xi'an Shaanxi
China The First Affiliated Hospital of Xiamen University Xiamen Fujian
China Henan Cancer Hospital Zhengzhou Henan
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (2)

Lead Sponsor Collaborator
Pierre Fabre Medicament Merck KGaA, Darmstadt, Germany

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Randomized Phase 2: Changes from baseline in blood Carcinoembryonic Antigen (CEA) and Cancer Antigen 19-9 (CA19-9) at the beginning of each cycle and at the end of treatment Screening (Day -28 to -1) through to study completion, approximately from 12 to 29 months
Other Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening Screening (Day -28 to Day -1)
Primary Safety Lead-in Phase: Incidence of Dose Limiting Toxicities (DLTs) during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI) Day 1 to Day 28
Primary Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR) Defined as the time from the date of randomization to the earliest documented disease progression as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., or death due to any cause Day 1 through to study completion, approximately from 12 to 29 months
Secondary Safety Lead-in Phase: Type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Informed consent through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of physical examinations Standard physical examinations on cardiovascular, respiratory, gastrointestinal, dermatological, ophthalmological and neurological systems will be performed and will be evaluated based on normal/abnormal and clinical significance observations. Number of participants with TEAEs related to abnormal or clinical significance observations to the physical examinations after the start of study drug will be reported. Day 1 through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in vital signs from baseline of vital sign examinations. Clinically notable elevated values: Systolic blood pressure (BP): = 160 mmHg and an increase = 20 mmHg from baseline; Diastolic BP: = 100 mmHg and an increase = 15 mmHg from baseline; Heart rate : = 120 beats/min (bpm) with increase from baseline of = 15 bpm; Weight (kg) increase from baseline of = 10%; Body temperature(°C) = 37.5°C). Clinically notable low values: Systolic BP: = 90 mmHg with decrease from baseline of = 20 mmHg; Diastolic BP: = 50 mmHg with decrease from baseline of = 15 mmHg; Heart rate: = 50 bpm with decrease from baseline of = 15 bpm; Weight: = 20% decrease from baseline; Body temperature [°C]: = 36 °C. Number of participants with TEAEs related to notable changes to the vital signs after the start of study drug will be reported. Day 1 through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of 12-lead electrocardiograms (ECGs) 12-lead ECGs will be obtained using an internationally recognized 12-lead cardiograph. Clinically notable ECG values: QT (ms) and QT interval (ms) corrected for heart rate using Fridericia's formula (QTcF) intervals (ms) : increase from baseline > 30 ms; increase from baseline > 60 ms, new > 450 ms, new > 480 ms, new > 500 ms. Heart rate (beats/min) : increase from baseline > 25% to a value > 100 bpm, decrease from baseline > 25% and to a value < 50 bpm. Number of participants with TEAEs related to abnormal or notable changes to ECG parameters after the start of study drug will be reported. Day 1 through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable changes in clinical safety laboratory parameters from baseline. Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 4.03 were graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death. Clinically notable shift is defined as a worsening from baseline by at least 2 grades, or to grade 3 or above. Day 1 through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Incidence of development of of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma by dermatological examinations This is to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma, as these have been reported to occur with selective BRAF inhibitor treatment. This assessment will be performed at screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit. Screening (Day -28 to -1) through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Performance status assessment using the Eastern Co-operative Oncology Group (ECOG) performance status scale Scale with a range from 0 to 5 with lower score mean a lower functional impairment, 5 corresponding to death Screening (Day -28 to -1) through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events (AEs) Day 1 until end of treatment, approximately 1 year
Secondary Safety Lead-in Phase: Plasma concentrations of encorafenib Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Serum concentrations of cetuximab Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase; Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib area under curve (AUC) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab area under curve (AUC) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib minimum concentration (Cmin) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab minimum concentration (Cmin) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib maximum concentration (Cmax) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab maximum concentration (Cmax) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Safety Lead-in Phase: Objective response rate (ORR) Objective response rate (ORR) defined as the proportion of participants with a best overall best response of either complete response (CR) or partial response (PR) as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Day 1 through to study completion, approximately from 18 to 35 months
Secondary Safety Lead-in Phase: Duration of Response (DOR) (months); defined for responders complete response (CR) or partial response (PR) only, is duration of time from the date of the first documented response to the earliest date of disease progression Duration of response, defined as the time from first documented response (complete response or partial response) to the earliest date of disease progression as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death due to underlying disease. Day 1 through to study completion, approximately from 18 to 35 months
Secondary Randomized Phase 2: Progression-free survival (PFS) Progression-free survival defined as the interval of time between the date of randomization to the earliest date of disease progression, as determined by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Overall Response Rate (ORR) Overall response rate (for confirmed and unconfirmed responses) defined as the proportion of participants with a confirmed (resp. unconfirmed) best overall response of either complete response or partial response, as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Duration of Response (DOR) Duration of response defined as the time from the date of the first documented response (complete response or partial response) to the earliest date of disease progression, as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Disease control rate (DCR) Disease control rate (DCR), defined as the proportion of participants with a best overall response of either complete response, partial response or stable disease (SD), as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Time to Response (TTR) Time to Response (for confirmed and unconfirmed responses) is defined as the time between date of randomization until first documented response of complete response (CR) or partial response (PR). Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Overall Survival (OS) Overall survival is defined as time from randomization until date of death due to any cause Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Type and severity of adverse events (AEs) and serious adverse events (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Informed consent date through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of physical examinations Standard physical examinations on cardiovascular, respiratory, gastrointestinal, dermatological, ophthalmological and neurological systems will be performed and will be evaluated based on normal/abnormal and clinical significance observations. Number of participants with TEAEs related to abnormal or clinical significance observations to the physical examinations after the start of study drug will be reported Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Incidence of treatment-emergent adverse events (TEAEs) related to notable changes in vital signs from baseline. Clinically notable elevated values: Systolic blood pressure (BP): = 160 mmHg and an increase = 20 mmHg from baseline; Diastolic BP: = 100 mmHg and an increase = 15 mmHg from baseline; Heart rate : = 120 beats/min (bpm) with increase from baseline of = 15 bpm; Weight (kg) increase from baseline of = 10%; Body temperature(°C) = 37.5°C). Clinically notable low values: Systolic BP: = 90 mmHg with decrease from baseline of = 20 mmHg; Diastolic BP: = 50 mmHg with decrease from baseline of = 15 mmHg; Heart rate: = 50 bpm with decrease from baseline of = 15 bpm; Weight: = 20% decrease from baseline; Body temperature [°C]: = 36 °C. Number of participants with TEAEs related to notable changes to the vital signs after the start of study drug will be reported. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes to electrocardiogram evaluations from baseline 12-lead ECGs will be obtained using an internationally recognized 12-lead cardiograph. Clinically notable ECG values: QT (ms) and QT interval (ms) corrected for heart rate using Fridericia's formula (QTcF) intervals (ms): increase from baseline > 30 ms; increase from baseline > 60 ms, new > 450 ms, new > 480 ms, new > 500 ms; Heart rate (beats/min): increase from baseline > 25% to a value > 100 bpm, decrease from baseline > 25% and to a value < 50 bpm. Number of participants with TEAEs related to abnormal or notable changes to ECG parameters after the start of study drug will be reported. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Incidence of treatment-emergent adverse events (TEAEs) related to notable changes in clinical safety laboratory parameters from baseline. Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 4.03 were graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death. Clinically notable shift is defined as a worsening from baseline by at least 2 grades, or to grade 3 or above. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Incidence of development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma by dermatological examinations This is to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma, as these have been reported to occur with selective BRAF inhibitor treatment. This assessment will be performed at screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: To determine the performance status using the Eastern Co-operative Oncology Group (ECOG) performance status scale. Scale with a range from 0 to 5 with lower score mean a lower functional impairment, 5 corresponding to death Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: To determine if there is any change from baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire scores EORTC QLQ-C30 consist of nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, nausea and vomiting); and a global health and Quality of Life (QoL) scale. Each scale in the questionnaire will be scored (0 to 100). High scores represents a high health/quality of life Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: To determine if there is any change from baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire scores. EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system has five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each is rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that describes the participant's health state. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: To determine if there is any change from baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) questionnaire scores FACT-C is a validated quality of life questionnaire for patient reported outcome assessment. FACT-C consists of 36 items, presented on a five-point Likert scale, in four domains of well-being (physical, emotional, social and functional) and the Colorectal Cancer Subscale. Higher score reflects a better quality of life. Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: To determine if there is any changes in the Patient Global Impression of Change (PGIC) questionnaire scores. PGIC will ask participants to evaluate their CRC symptoms since starting study intervention according to a seven-point verbal rating scale (VRS): 1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse Day 1 through to study completion, approximately from 12 to 29 months
Secondary Randomized Phase 2: Plasma concentrations of encorafenib Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Serum concentrations of cetuximab Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2; Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib area under curve (AUC) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab area under curve (AUC) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib minimum concentration (Cmin) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab minimum concentration (Cmin) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib maximum concentration (Cmax) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab maximum concentration (Cmax) in Chinese participants Day 1 of Cycles 1 and 2; Each cycle = 28 days
Secondary Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data Day 1 through to study completion, approximately from 12 to 29 months
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2